|
1
|
Cervello M, McCubrey JA, Cusimano A,
Lampiasi N, Azzolina A and Montalto G: Targeted therapy for
hepatocellular carcinoma: Novel agents on the horizon. Oncotarget.
3:236–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang Q, Shi S, Yen Y, Brown J, Ta JQ and
Le AD: A subpopulation of CD133+ cancer stem-like cells
characterized in human oral squamous cell carcinoma confer
resistance to chemotherapy. Cancer Lett. 289:151–160. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Di Maio M, Daniele B and Perrone F:
Targeted therapies: Role of sorafenib in HCC patients with
compromised liver function. Nat Rev Clin Oncol. 6:505–506. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bioulac-Sage P, Laumonier H, Couchy G, Le
Bail B, Sa Cunha A, Rullier A, Laurent C, Blanc JF, Cubel G,
Trillaud H, et al: Hepatocellular adenoma management and phenotypic
classification: The Bordeaux experience. Hepatology. 50:481–489.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scanga A and Kowdley K: Sorafenib: A
glimmer of hope for unresectable hepatocellular carcinoma?
Hepatology. 49:332–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43–9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Panka DJ, Wang W, Atkins MB and Mier JW:
The Raf inhibitor BAY 43–9006 (Sorafenib) induces
caspase-independent apoptosis in melanoma cells. Cancer Res.
66:1611–1619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Adnane L, Trail PA, Taylor I and Wilhelm
SM: Sorafenib (BAY 43–9006, Nexavar), a dual-action inhibitor that
targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases
VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407:597–612.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wilhelm S, Carter C, Lynch M, Lowinger T,
Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery
and development of sorafenib: A multikinase inhibitor for treating
cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang W, Konopleva M, Shi YX, McQueen T,
Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J,
et al: Mutant FLT3: A direct target of sorafenib in acute
myelogenous leukemia. J Natl Cancer Inst. 100:184–198. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schönfeld P, Schild L and Bohnensack R:
Expression of the ADP/ATP carrier and expansion of the
mitochondrial (ATP + ADP) pool contribute to postnatal maturation
of the rat heart. Eur J Biochem. 241:895–900. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chevrollier A, Loiseau D, Reynier P and
Stepien G: Adenine nucleotide translocase 2 is a key mitochondrial
protein in cancer metabolism. Biochim Biophys Acta. 1807:562–567.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jang JY, Jeon YK, Lee CE and Kim CW: ANT2
suppression by shRNA may be able to exert anticancer effects in HCC
further by restoring SOCS1 expression. Int J Oncol. 42:574–582.
2013.PubMed/NCBI
|
|
18
|
Baik SH, Lee J, Lee YS, Jang JY and Kim
CW: ANT2 shRNA downregulates miR-19a and miR-96 through the
PI3K/Akt pathway and suppresses tumor growth in hepatocellular
carcinoma cells. Exp Mol Med. 48:e2222016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jang JY, Lee YS, Jeon YK, Lee K, Jang JJ
and Kim CW: ANT2 suppression by shRNA restores miR-636 expression,
thereby downregulating Ras and inhibiting tumorigenesis of
hepatocellular carcinoma. Exp Mol Med. 45:e32013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ng KK, Poon RT, Chan SC, Chok KS, Cheung
TT, Tung H, Chu F, Tso WK, Yu WC, Lo CM, et al: High-intensity
focused ultrasound for hepatocellular carcinoma: A single-center
experience. Ann Surg. 253:981–987. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liao XH, Li YQ, Wang N, Zheng L, Xing WJ,
Zhao DW, Yan TB, Wang Y, Liu LY, Sun XG, et al: Re-expression and
epigenetic modification of maspin induced apoptosis in MCF-7 cells
mediated by myocardin. Cell Signal. 26:1335–1346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liao XH, Wang Y, Wang N, Yan TB, Xing WJ,
Zheng L, Zhao DW, Li YQ, Liu LY, Sun XG, et al: Human chorionic
gonadotropin decreases human breast cancer cell proliferation and
promotes differentiation. IUBMB Life. 66:352–360. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liao XH, Xiang Y, Yu CX, Li JP, Li H, Nie
Q, Hu P, Zhou J and Zhang TC: STAT3 is required for
MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis
in breast cancer cells. Oncotarget. Feb 2–2017.(Epub ahead of
print).
|
|
24
|
Liao XH, Li JY, Dong XM, Wang X, Xiang Y,
Li H, Yu CX, Li JP, Yuan BY, Zhou J, et al: ERα inhibited
myocardin-induced differentiation in uterine fibroids. Exp Cell
Res. 350:73–82. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liao XH, Lu DL, Wang N, Liu LY, Wang Y, Li
YQ, Yan TB, Sun XG, Hu P and Zhang TC: Estrogen receptor α mediates
proliferation of breast cancer MCF-7 cells via a
p21/PCNA/E2F1-dependent pathway. FEBS J. 281:927–942. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xiang Y, Lu DL, Li JP, Yu CX, Zheng DL,
Huang X, Wang ZY, Hu P, Liao XH and Zhang TC: Myocardin inhibits
estrogen receptor alpha-mediated proliferation of human breast
cancer MCF-7 cells via regulating MicroRNA expression. IUBMB Life.
68:477–487. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren ZG, Dong SX, Han P and Qi J: miR-203
promotes proliferation, migration and invasion by degrading SIK1 in
pancreatic cancer. Oncol Rep. 35:1365–1374. 2016.PubMed/NCBI
|
|
28
|
Lu Y, Chopp M, Zheng X, Katakowski M,
Buller B and Jiang F: MiR-145 reduces ADAM17 expression and
inhibits in vitro migration and invasion of glioma cells.
Oncol Rep. 29:67–72. 2013.PubMed/NCBI
|
|
29
|
Suetsugu A, Nagaki M, Aoki H, Motohashi T,
Kunisada T and Moriwaki H: Characterization of CD133+
hepatocellular carcinoma cells as cancer stem/progenitor cells.
Biochem Biophys Res Commun. 351:820–824. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J and
Li J: Cancer stem/progenitor cells are highly enriched in
CD133+CD44+ population in hepatocellular
carcinoma. Int J Cancer. 126:2067–2078. 2010.PubMed/NCBI
|
|
31
|
Yamashita T, Ji J, Budhu A, Forgues M,
Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al:
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating
cells with stem/progenitor cell features. Gastroenterology.
136:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 75:843–854. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pasquinelli AE, Reinhart BJ, Slack F,
Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B,
Müller P, et al: Conservation of the sequence and temporal
expression of let-7 heterochronic regulatory RNA. Nature.
408:86–89. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu LL, Lu SX, Li M, Li LZ, Fu J, Hu W,
Yang YZ, Luo RZ, Zhang CZ and Yun JP: FoxD3-regulated microRNA-137
suppresses tumour growth and metastasis in human hepatocellular
carcinoma by targeting AKT2. Oncotarget. 5:5113–5124. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Azumi J, Tsubota T, Sakabe T and Shiota G:
miR-181a induces sorafenib resistance of hepatocellular carcinoma
cells through downregulation of RASSF1 expression. Cancer Sci.
107:1256–1262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Emma MR, Iovanna JL, Bachvarov D, Puleio
R, Loria GR, Augello G, Candido S, Libra M, Gulino A, Cancila V, et
al: NUPR1, a new target in liver cancer: Implication in controlling
cell growth, migration, invasion and sorafenib resistance. Cell
Death Dis. 7:e22692016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu J, Cui X, Qu L, Hua L, Wu M, Shen Z,
Lu C and Ni R: Overexpression of DLX2 is associated with poor
prognosis and sorafenib resistance in hepatocellular carcinoma. Exp
Mol Pathol. 101:58–65. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu FQ, Fang T, Yu LX, Lv GS, Lv HW, Liang
D, Li T, Wang CZ, Tan YX, Ding J, et al: ADRB2 signaling promotes
HCC progression and sorafenib resistance by inhibiting autophagic
degradation of HIF1α. J Hepatol. 65:314–324. 2016. View Article : Google Scholar : PubMed/NCBI
|
